Status:

RECRUITING

REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

Lead Sponsor:

Beijing Tiantan Hospital

Collaborating Sponsors:

National Natural Science Foundation of China

Beijing Municipal Science & Technology Commission

Conditions:

Stroke

Vascular Occlusion

Eligibility:

All Genders

18+ years

Brief Summary

The aim of the study was to establish a clinical and advanced imaging database of acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulat...

Detailed Description

The time-window of mechanical thrombectomy for ischemic stroke has extended from 4.5 hours to 24 hours based on the results of the DAWN and DEFUSE 3 trials. However, evidence on the effectiveness and ...

Eligibility Criteria

Inclusion

  • Older than 18 years;
  • Perfusion imaging completed including CTA+CTP or MRA+PWI+DWI before thrombectomy
  • Large vessel occlusion of cerebral anterior circulation (ICA, MCA-M1 or MCA-M2) confirmed by CTA or MRA, planned to receive or received stenting or aspiration thrombectomy
  • Time intervals ≤ 24 hours from stroke onset to groin puncture.(fulfilled the inclusion of DAWN or DEFUSE 3 trial if the time intervals from stroke onset to groin puncture was ≥6 hours)
  • mRS score ≤2 before admission
  • Informed consent obtained for longitudinal enrolled patients, waived of consent for retrospectively included cases

Exclusion

  • Had a history of infective disease, immunity disease, radiotherapy at head or neck, carotid dissection or other carotid disease.
  • Unable to receive CT or MR scan due to heart failure, cardiac pacemaker, metal implants or claustrophobia, etc.
  • Unable to be injected with contrast agent due to allergy, renal dysfunction, etc.
  • Unlikely to adhere to the study protocol or follow-up ( life expectancy ≤ 3 months)
  • Already participated in other drug trials

Key Trial Info

Start Date :

February 23 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

1600 Patients enrolled

Trial Details

Trial ID

NCT05311605

Start Date

February 23 2023

End Date

December 31 2024

Last Update

March 21 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yunyun Xiong

Beijing, China